Abstract
1. Carbohydrate deficient transferrin (CDTect-RIA, Pharmacia) was compared with an Immuno-luminometric assay for isotransferrin separated by a short column Con-A sepharose which we have called alcohol mediated triantennary transferrin (AMT). 2. 101 in-patients with alcohol dependency syndrome (alcohol consumption of more than 60 g/day) were grouped according to the time of abstinence A1 (0–7 days), A2 (8–14 days), A3 (≥15 days). Serum samples were obtained at admission (U0) and under abstinent conditions after 10–20 days (U1). All groups were controlled for AMT, CDT, GGT, MCV. Control groups were 30 inpatients with non alcoholic liver disease (NALD) and 31 healthy volunteers (alcohol consumption of less than 20g/day). 3. Results showed for CDT and AMT highly significant differences between short abstinence period (group A1) and more than two weeks abstinence (group A3) alcoholics and between group A1 and healthy controls. In group A1 CDT was significantly elevated (P ≤.001) compared to NALD group whereas AMT showed no differences. 4. CDT (cut off 22 mg/l) showed a high diagnostic specifity (A1/controls 97%, A1/NALD 83%, A1/A3 78%) but only a diagnostic sensitivity of 61 %. AMT (cut off 260 mg/l) revealed a diagnostic test sensitivity of 74%. The diagnostic test specifity of AMT was inferior to CDT (A1/controls 74%, A1/NALD 50%, A1/A3 70%). 5. Initial CDT and AMT values in alcoholics were highly correlated (P ≤.001) with time of abstinence. CDT and AMT decline was correlated with time of abstinence. CDT was proved for high significant (P ≤.001) decline over a longer period of abstinence (11–30 days) while AMT decline was significant (P = .008) only in early abstinence (0–10 days). Presence of a withdrawal syndrome was highly correlated (P ≤.01) with CDT values above 22 mg/l and AMT values above 260 mg/l. Furthermore in selected follow up cases it was shown that AMT seemed to be a more sensitive indicator for short alcoholic relapses than CDT.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Progress in Neuropsychopharmacology & Biological Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.